Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma Meeting Abstract
| Authors: | Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; Sridhar, S. S.; Pappot, H.; Gurney, H. P.; Bedke, J.; van der Heijden, M. S.; Campbell, M.; Wu, C.; Matsangou, M.; Petrylak, D. P. |
| Abstract Title: | Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S710 |
| End Page: | S711 |
| Language: | English |
| ACCESSION: | WOS:000700527701164 |
| DOI: | 10.1016/j.annonc.2021.08.094 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract #698P -- Source: Wos |
